Levi-Setti PE

No ORCID on file · 4 papers in corpus
observational 2026
Clinical use of recombinant human luteinizing hormone beyond hypogonadotropic hypogonadism: a multicenter descriptive analysis from five Italian fertility centers
Reproductive biology and endocrinology : RB&E ·doi:10.1186/s12958-026-01551-y

BACKGROUND: Recombinant human luteinizing hormone (rLH) was originally introduced to supplement recombinant human follicle-stimulating hormone (rFSH) for controlled ovarian stimulation (COS) in patients with hypogonadotropic hypogonadism. P…

observational 2024
Diminished ovarian reserve is associated to euploidy rate: a single center study
Frontiers in endocrinology ·doi:10.3389/fendo.2024.1535776

BACKGROUND: Reproductive success shows a well-documented decline with advancing maternal age, primarily due to chromosomal abnormalities (aneuploidies) in embryos. While ovarian reserve markers such as Anti-Müllerian Hormone (AMH) and Antra…

meta-analysis 2024
Efficacy and safety of follitropin delta for ovarian stimulation in vitro fertilization/ intracytoplasmic sperm injection cycles: a systematic review with meta-analysis
Journal of ovarian research ·doi:10.1186/s13048-024-01372-w

BACKGROUND: Follitropin delta is a novel recombinant follicle stimulating hormone preparation uniquely expressed in a human fetal retinal cell line by recombinant DNA technology. To date, no systematic review was available about the safety …

meta-analysis 2024
Untangling the independent effect of endometriosis, adenomyosis, and ART-related factors on maternal, placental, fetal, and neonatal adverse outcomes: results from a systematic review and meta-analysis
Human Reproduction Update ·doi:10.1093/humupd/dmae024

BACKGROUND: Women with endometriosis may constitute a group at a particularly increased risk of pregnancy-related complications. Furthermore, women selected for assisted reproductive technology (ART) are exposed to additional endocrinologic…